Abbott i-STAT 1 System Manual page 466

Notes:
1) Hydroxyurea is a DNA synthesis inhibitor used in the treatment of various forms of cancer, sickle cell
anemia, and HIV infection. This drug is used to treat malignancies including melanoma, metastatic ovar-
ian cancer, and chronic myelogenous leukemia. It is also used in the treatment of polycythemia vera,
thrombocythemia, and psoriasis. At typical doses ranging from 500 mg to 2 g/day, concentrations of
hydroxyurea in patients' blood may be sustained at approximately 100 to 500 μmol/L. Higher concentra-
tions may be observed soon after dosing or at higher therapeutic doses.
2) Glycolic acid is a product of ethylene glycol metabolism. Unexpected increased lactate concentrations
caused by glycolic acid may be a clue to the possibility of ethylene glycol ingestion as the cause of an
otherwise unknown high anion gap metabolic acidosis. In a study of 35 patients who had ingested eth-
21,22
ylene glycol, initial glycolic acid concentrations of 0 to 38 mmol/L corresponded to ethylene glycol levels
of 0.97 - 130.6 mmol/L.
22
3) Bromide has been tested at two levels; the CLSI recommended level and a therapeutic plasma con-
centration level of 2.5 mmol/L. The latter is the peak plasma concentration associated with halothane
anesthesia, in which bromide is released. APOC has not identified a therapeutic condition that would
lead to levels consistent with the CLSI recommended level. Bromide at a concentration of 37.5 mmol/L
decreased i-STAT lactate results, while a therapeutic range of bromide (2.5 mmol/L) did not significantly
interfere with i-STAT lactate results.
* It is possible that other interfering substances may be encountered. The degree of interference at concentrations other than those listed might not be
predictable.
LAC - 4
Art: 714184-01O Rev. Date: 15-Jul-16